These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9224743)
1. Role of CD44 in nonpalpable T1a and T1b breast cancer. Lyzak JS; Yaremko ML; Recant W; Baunoch DA; Joseph L Hum Pathol; 1997 Jul; 28(7):772-8. PubMed ID: 9224743 [TBL] [Abstract][Full Text] [Related]
2. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Port ER; Tan LK; Borgen PI; Van Zee KJ Ann Surg Oncol; 1998; 5(1):23-7. PubMed ID: 9524703 [TBL] [Abstract][Full Text] [Related]
3. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study. Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459 [TBL] [Abstract][Full Text] [Related]
5. Pathology and behavior of small breast carcinomas. Meyer JS; Fahrner M; Daniel FC Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Greco M; Agresti R; Cascinelli N; Casalini P; Giovanazzi R; Maucione A; Tomasic G; Ferraris C; Ammatuna M; Pilotti S; Menard S Ann Surg; 2000 Jul; 232(1):1-7. PubMed ID: 10862188 [TBL] [Abstract][Full Text] [Related]
7. The role of axillary dissection in mammographically detected carcinoma. Pandelidis SM; Peters KL; Walusimbi MS; Casady RL; Laux SV; Cavanaugh SH; Bauer TL J Am Coll Surg; 1997 Apr; 184(4):341-5. PubMed ID: 9100677 [TBL] [Abstract][Full Text] [Related]
8. T1a and T1b breast cancer: a twelve-year experience. Visser TJ; Haan M; Keidan R; Lucas R; Ingold J; Glover J; Riggo P Am Surg; 1997 Jul; 63(7):621-6. PubMed ID: 9202537 [TBL] [Abstract][Full Text] [Related]
9. Effect of lymphatic mapping on diagnosis and treatment of patients with T1a, T1b favorable breast cancer. Jakub JW; Ebert MD; Diaz NM; Cantor A; Reintgen DS; Dupont EL; Shons AR; Cox CE Ann Surg; 2003 Jun; 237(6):838-41; discussion 841-3. PubMed ID: 12796580 [TBL] [Abstract][Full Text] [Related]
10. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Silverstein MJ; Gierson ED; Waisman JR; Senofsky GM; Colburn WJ; Gamagami P Cancer; 1994 Feb; 73(3):664-7. PubMed ID: 8299088 [TBL] [Abstract][Full Text] [Related]
11. The interaction between aromatase, metalloproteinase 2,9 and CD44 in breast cancer. Bagnoli F; Oliveira VM; Silva MA; Taromaru GC; Rinaldi JF; Aoki T Rev Assoc Med Bras (1992); 2010; 56(4):472-7. PubMed ID: 20835647 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer. Wu XJ; Li XD; Zhang H; Zhang X; Ning ZH; Yin YM; Tian Y J Int Med Res; 2015 Apr; 43(2):173-9. PubMed ID: 25571897 [TBL] [Abstract][Full Text] [Related]
13. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Afify AM; Tate S; Durbin-Johnson B; Rocke DM; Konia T Int J Biol Markers; 2011; 26(1):50-7. PubMed ID: 21279958 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325 [TBL] [Abstract][Full Text] [Related]
15. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815 [TBL] [Abstract][Full Text] [Related]
16. Predictors of axillary lymph node metastasis in T1 breast carcinoma. Shoup M; Malinzak L; Weisenberger J; Aranha GV Am Surg; 1999 Aug; 65(8):748-52; discussion 752-3. PubMed ID: 10432085 [TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625 [TBL] [Abstract][Full Text] [Related]
18. Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Mincey BA; Bammer T; Atkinson EJ; Perez EA Arch Surg; 2001 Jul; 136(7):779-82. PubMed ID: 11448390 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890 [TBL] [Abstract][Full Text] [Related]
20. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]